May 5, 2022
|
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
|
Apr 28, 2022
|
Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022
|
Apr 25, 2022
|
Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)
|
Apr 12, 2022
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Apr 11, 2022
|
Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor
|
Apr 7, 2022
|
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings
|
Apr 4, 2022
|
Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
|
Mar 9, 2022
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Mar 2, 2022
|
Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference
|
Feb 28, 2022
|
Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
|